European Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual Property (IP) portfolio as European Patent Application No. 14851547.1 has been granted. The patent will be set to expire in October 7, 2034, subject to patent term adjustment or extension. "This is a pivotal event for Cellect and perhaps one of the most crucial developments for us  as we have secured IP protection over the second component of the Apograft™ effects – the activation of the stem and progenitor cells," commented Dr. Shai Yarkoni, Chief Executive Officer.  "While the extensive issued patents cover the accurate elimination (negative selection) of the mature cells and therefor enables SAFETY, this patent covers the increased ACTIVITY (positive selection=efficacy) of the regenerative capacity of the stem and progenitor cells.  Combined with our previously issued patents, our IP now cover the dual effects of the apoptotic proteins with a single, robust, and cost-effective process that is achieved outside of the patient's body.    The clinical and economic benefits are multi-fold as we have demonstrated increased safety and efficacy of the cell product by developing a robust, non-expensive and user-friendly process and product.